AstraZeneca said its Phase III CARDIO-TTRansform trial of Wainua (with Ionis) in transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint for the composite cardiovascular outcome. The failure to achieve the trial’s main endpoint is a clear clinical setback that is likely to weigh on near-term expectations for the program.
AstraZeneca said its Phase III CARDIO-TTRansform trial of Wainua (with Ionis) in transthyretin-mediated amyloid cardiomyopathy did not meet the primary efficacy endpoint for the composite cardiovascular outcome. The failure to achieve the trial’s main endpoint is a clear clinical setback that is likely to weigh on near-term expectations for the program.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
